SAB BIOTHERAPEUTICS, INC. (SABSW) Return on equity 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABSW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
8.8%FY2025 · since FY2020: 51.6% → 8.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.8% | +140.1 pp |
| FY2024 | -131.3% | -57.7 pp |
| FY2023 | -73.6% | -13.3 pp |
| FY2022 | -60.3% | -15.9 pp |
| FY2021 | -44.5% | -96.0 pp |
| FY2020 | 51.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SABSW financial trends
SABSW RevenueSABSW Net incomeSABSW Net marginSABSW Gross profitSABSW Gross marginSABSW Operating incomeSABSW Operating marginSABSW Operating cash flowSABSW Free cash flowSABSW Capital expendituresSABSW Stock buybacksSABSW Dividends paidSABSW Total assetsSABSW Total liabilitiesSABSW Shareholders’ equitySABSW overview →